|
MechanismHMG-CoA reductase inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date17 Jul 2003 |
100 Clinical Results associated with Nanjing Chenxiang Medicine Research Co., Ltd.
0 Patents (Medical) associated with Nanjing Chenxiang Medicine Research Co., Ltd.
100 Deals associated with Nanjing Chenxiang Medicine Research Co., Ltd.
100 Translational Medicine associated with Nanjing Chenxiang Medicine Research Co., Ltd.